Grindeks does not sell directly to African pharmacies. It does not have distributors in Dar es Salaam or Harare. Yet Latvian-manufactured medicines end up in hospitals across Tanzania and Zimbabwe. The pathway is institutional, and it works differently from anything else in the Latvia-SADC corridor.
The Company
Grindeks is the largest pharmaceutical company in the Baltics, headquartered in Riga. The company manufactures active pharmaceutical ingredients (APIs) and finished dosage forms across production sites in Latvia and Estonia. It exports to over 100 countries.
In February 2025, Grindeks announced expansion to new export markets worldwide, signaling a strategic push beyond its traditional European and CIS customer base.
The WHO Prequalification Gateway
Grindeks is a WHO-prequalified supplier of injectable medicines, including oxytocin — a drug critical for preventing postpartum hemorrhage, which remains a leading cause of maternal mortality in Sub-Saharan Africa.
WHO Prequalification is not a marketing badge. It is a rigorous assessment program that evaluates whether a manufacturer's products, production processes, and quality systems meet international standards. Only prequalified manufacturers can supply medicines through UN procurement agencies.
This is the gateway. Once prequalified, a manufacturer becomes eligible for orders from UNFPA (United Nations Population Fund) and UNICEF, which procure medicines in bulk for distribution to health systems in developing countries.
How Latvian Medicines Reach SADC
Products from Grindeks reach Tanzania and Zimbabwe through UNFPA and UNICEF procurement channels. The flow is: Grindeks manufactures in Latvia, ships to UN agency distribution hubs, and the agencies deliver to national health systems.
This is a fundamentally different model from MikroTik (which sells through local distributors) or LATRAPS (which ships bulk commodities directly). Grindeks reaches Africa through institutional procurement. There is no Grindeks sales office in Africa. There does not need to be.
What This Means for SADC
The pharmaceutical supply chain in Sub-Saharan Africa is dominated by Indian and Chinese generic manufacturers. They have the scale, the regulatory approvals, and the distribution networks. A Latvian manufacturer competing in this space is unusual.
Grindeks fills a specific niche: WHO-prequalified injectable medicines where supply reliability matters. Oxytocin, for instance, requires cold chain handling and consistent quality. Health systems in Tanzania and Zimbabwe need suppliers that can meet those requirements and that have passed WHO's evaluation process.
For SADC countries, the significance is access to affordable, quality-assured medicine from a non-traditional source. For Latvia, it represents a commercial presence in African health systems that operates entirely through multilateral channels — no bilateral trade agreement required.
The money is modest compared to grain or telecom equipment exports. But the impact per shipment is disproportionately high. A container of oxytocin reaching a rural Tanzanian hospital prevents maternal deaths. That is not a trade statistic. It is a measurable health outcome with a Latvian manufacturer's name on the vial.